Results showed significant improvements in liver stiffness, liver enzymes, metabolic parameters, TNF-α, and liver fibrosis biomarkers (hyaluronic acid and TGF-β1) in the montelukast group, with good tolerability observed (122). Here, TGFB1 is linked to Hepatic fibrosis.